1stOncology™: Cancer Intelligence Service – Page 13824 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019

On April 17, 2019 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will host a key opinion leader (KOL) breakfast symposium focused on the unmet need, treatment landscape and opportunities for selective cyclin-dependent kinase 7 (CDK7) inhibition in ovarian and breast cancers on Wednesday, April 24, 2019 from 8:30 – 10:30 a.m. ET in New York City (Press release, Syros Pharmaceuticals, APR 17, 2019, View Source [SID1234535180]). Syros is currently evaluating SY-1365, a first-in-class selective CDK7 inhibitor, in a Phase 1 clinical trial as a single agent and in combination with other therapies in multiple ovarian and breast cancer patient populations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The event will feature presentations from Dejan Juric, M.D., Medical Oncologist and Director at the Termeer Center for Targeted Therapies, Massachusetts General Hospital and Charles A. Leath, III, M.D., M.S.P.H., Professor in the Division of Gynecologic Oncology and Ellen Gregg Shook Culverhouse Chair in Gynecologic Oncology at the University of Alabama Medical Center. Additionally, members of the Syros management team will provide an overview of SY-1365, including preclinical and clinical data supporting its ongoing development in ovarian and breast cancer patients, and SY-5609, its oral selective CDK7 inhibitor, which is expected to enter a Phase 1 oncology study in early 2020.

A live webcast of the event will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following each presentation.

SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer

On April 17, 2019 SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, reported an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC) (Press release, SK biopharmaceuticals, APR 17, 2019, View Source [SID1234535175]).

Under the agreement, twoXAR will use its AI discovery technology to identify a set of initial candidates with the potential to treat lung cancer through novel biological mechanisms of action. After screening, SK Biopharmaceuticals plans to use its internal AI Drug Design technology to optimize a lead candidate and then conduct IND-enabling studies. SK Biopharmaceuticals will retain exclusive worldwide rights to develop and commercialize the drug candidate. twoXAR will receive an upfront payment and will be eligible for development and commercial milestone payments in addition to royalties.

Lung cancer is the leading cause of cancer deaths globally with a 5-year survival rate of less than 18%1. The two main types of lung cancer are small cell and non-small cell, accounting for 10-15% and 85% of all lung cancers, respectively. Treatment is based on the lung cancer stage and subtype, and generally consists of surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. However, the disease is known to become resistant to current lines of therapy. It is estimated that there were 2 million new lung cancer cases diagnosed worldwide in 20182.

"AI-powered approaches are pioneering new, more efficient ways to find promising new drug candidates and are enabling SK Biopharmaceuticals to build the next-generation pharmaceutical company," said Cheol-Young Maeng, PhD, Vice President of Cancer Research at SK Biopharmaceuticals. "We are excited to combine twoXAR’s and SK Biopharmaceuticals’ technologies because of the potential to progress drug candidates from hypotheses to IND-enabling studies faster than ever before."

"SK Biopharmaceuticals’ focus on powering end-to-end drug discovery and development by adopting new technologies to foster efficiencies makes them an ideal partner for twoXAR," said Andrew A. Radin, Co-Founder and CEO of twoXAR. "As the leading cause of cancer death, lung cancer is a serious disease with high unmet need. We are pleased to be working with SK Biopharmaceuticals, who’s achieved remarkable success from discovery to filing for FDA approval, to combine our complementary platforms with a shared commitment to rapidly identify, validate, and develop novel treatments for lung cancer patients in need."

Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8

On April 17, 2019 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will report its first quarter 2019 financial results on Wednesday, May 8, 2019, after the U.S. financial markets close (Press release, Five Prime Therapeutics, APR 17, 2019, View Source [SID1234535174]). Five Prime will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. (ET) / 1:30 p.m. (PT) to discuss the company’s financial results and provide a general business update.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company’s website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID: 7585986.

The archived conference call will be available on Five Prime’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

Pulse Biosciences to Report First Quarter 2019 Operational Highlights and Financial Results

On April 17, 2019 Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX System reported that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April 30, 2019 (Press release, Pulse Biosciences, APR 17, 2019, View Source [SID1234535173]). Pulse Biosciences management will host a conference call at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).

Analysts and investors can participate in the conference call by dialing (844) 494-0190 (domestic) and (508) 637-5580 (international) using the conference ID# 3466369. The conference call can also be accessed live on the Investor Relations section of the Pulse Biosciences website at www.PulseBiosciences.com.

Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting

On April 17, 2019 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported several presentations at the upcoming 2019 American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting that will be held from April 29 to May 2, 2019 in Washington, DC (Press release, Cellectis, APR 17, 2019, View Source [SID1234535172]). Details on date and times of presentations can be found below.

An oral presentation will demonstrate the potential of UCARTCS1A as a treatment approach for patients with Multiple Myeloma. This presentation follows the recent clearance of the UCARTCS1A IND by the FDA, IRB approvals as well as clinical batch release.

A poster presentation will showcase Cellectis’ allogeneic CAR T-cell manufacturing expertise, focusing on a novel, straightforward and efficient strategy to generate Universal CAR T-Cells. This exemplifies how Cellectis’ cutting-edge gene editing and cell engineering capabilities can be leveraged to improve key features of our product candidates.

Furthermore, Julianne Smith, Ph.D., Vice President of Translational Sciences, will be participating in a corporate review session at the Gene Editing Workshop on Sunday, April 28, 2019 from 5:00 PM to 6:00 PM EDT. Julianne will also be giving a presentation entitled "Allogeneic Gene-Edited CAR T-Cells: From Preclinical to Clinical Proof of Concept" on Tuesday, April 30 from 8:00 AM to 8:30 AM EDT during the Scientific Symposium "Towards the Holy Grail of Cancer Gene Therapies: Universal Cells, Targeted Vectors and Solid Tumor CART Efficacy".

Finally, Philippe Duchateau, Ph.D., Chief Scientific Officer of Cellectis, will be participating in the Scientific Symposium "Innovation in First Time in Human Study Clinical Studies" held on Monday, April 29 with a presentation titled "Universal Gene-Edited CAR T-Cell Immunotherapy" from 9:30 AM to 10:00 AM EDT.

Oral presentation details:

UCARTCS1A: Allogeneic CAR T-Cells Targeting CS1 as Treatment for Multiple Myeloma
Roman Galetto1, Rohit Mathur2, Mathilde Dusseaux1, Isabelle Chion-Sotinel1, Jing Yang2, Diane Le Clerre1, Stephanie Filipe1, Sattva Neelapu2, Julianne Smith3, Agnès Gouble1

1Cellectis SA, Paris, France
2MD Anderson Cancer Center, Houston, TX, USA
3Cellectis Inc, New York, NY, USA

Monday, April 29 – 3 :45 PM – 4 :00 PM EDT
CAR-T Cell Therapies for Cancer Session
Room: International Ballroom West
Abstract Number: 139

Poster presentation details:

A Straightforward and Efficient Strategy to Generate Universal CAR T-Cells
Alexandre Juillerat1, Ming Yang1, Diane Tkach1, Mohit Sachdeva1, Alex Boyne1, Julien Valton1, Laurent Poirot2, Philippe Duchateau2

1Cellectis, Inc., 430E, 29th street, New York, NY 10016, USA
2Cellectis, 8 rue de la croix Jarry, 75013 Paris, France

Wednesday, May 1 – 5 :00 PM – 6 :00 PM EDT
Cell Therapies III Session
Room: Columbia Hall
Abstract Number: 874

Abstracts are available on the ASGCT (Free ASGCT Whitepaper) website. The two abstract presentations (oral and poster) to be presented at the 2019 ASGCT (Free ASGCT Whitepaper) Annual Meeting will be available on the Cellectis website after May 1, 2019.